Core Insights - Boston Scientific has signed up for the 9th China International Import Expo (CIIE) in 2024, marking its seventh consecutive participation, reflecting its evolving role as a "new foreign enterprise" in China [1][3] Group 1: Company Strategy and Innovation - The company aims to shift from merely introducing global advanced technologies to co-creating value locally, embedding Chinese clinical needs into the global R&D system [1][3] - Boston Scientific will showcase over 80 innovative products at the expo, covering various medical fields, with 6 products making their debut [2][3] - Since its participation began, 22 products have transitioned from exhibition to commercialization, with a new manufacturing base in Shanghai expected to start mass production by 2026 [3] Group 2: AI and Digital Initiatives - The company launched the first medical device knowledge graph and a digital education platform, eLibrary 2.0, which includes a comprehensive medical knowledge base and an AI-driven question-answering system [5] - AI is being integrated into core product lines, such as the HeartLogic heart failure monitoring technology, which can predict potential heart failure events up to 34 days in advance and reduce hospitalization rates by 67% [5] Group 3: Clinical Collaboration and Education - Boston Scientific hosted a forum on stroke prevention and TCAR (Transcarotid Artery Revascularization) techniques, engaging top clinical experts to discuss advancements in stroke treatment [6] - The company emphasizes its commitment to innovation in the carotid artery stenosis treatment field, aiming to enhance the stroke prevention system in China through technological and academic collaboration [6]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 2025年3月12日， 苏州无双医疗设备有限公司 （以下简称"无双医疗"）宣布 完成C轮近1.5亿元人民币融资 。 本轮融资由 天士力资本 领投，现有股东 启明创投、苏高新金控、康裕资本 继续加持。融资资金将主要用于公 司新一代产品研发和商业化 ，进一步巩固其在行业内的领先地位。 # 公司介绍 苏州无双医疗设备有限公司 成立于2017年7月11日，总部位于苏州高新区医疗器械产业园。公司是一家专注于 心脏节律管理（CRM） 相关医疗器械研发和产业化的硬科技企业。无双医疗致力于打造中国CRM高端医疗器 械品牌，产品线涵盖 植入式心律转复除颤器（ICD）、植入式心电事件监测器（ICM）以及植入式心脏起搏 器（Pacemaker） 等。 核心产品与技术 融资历程 天使轮： 2017年完成天使轮融资，投资方包括北极光创投等。 A轮： 2020年完成A轮融资，投资方包括启明创投，资金用于加速核心产品的研发和临床试验。 B轮： 2022年完成B轮融资，投资 ...